NCT06967805 - WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

BIOLOGICAL

MTX-463

MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.

OTHER

Placebo

Trial Locations (17)

2145

RECRUITING

WISPer site in Westmead, Australia, Westmead

3004

RECRUITING

WISPer site in Melbourne, Australia, Melbourne

4120

RECRUITING

WISPer site in Greenslopes, Australia, Greenslopes

6056

RECRUITING

WISPer site in Midland, Australia, Midland

10032

RECRUITING

WISPer site in New York, NY, New York

27403

RECRUITING

WISPer site in Greensboro, NC, Greensboro

33470

RECRUITING

WISPer site in Loxahatchee, FL, Loxahatchee Groves

61822

RECRUITING

WISPer site in Champaign, IL, Champaign

66160

RECRUITING

WISPer site in Kansas City, KS, Kansas City

71103

RECRUITING

WISPer site in Shreveport, LA, Shreveport

73104

RECRUITING

WISPer site in Oklahoma City, OK, Oklahoma City

75204

RECRUITING

WISPer site in Dallas, TX, Dallas

85032

RECRUITING

WISPer site in Phoenix, AZ, Phoenix

92203

RECRUITING

WISPer Site in Palm Springs, CA, Palm Springs

92663

RECRUITING

WISPer site in Newport Beach, CA, Newport Beach

L1S 2J5

RECRUITING

WISPer site in Ajax, ON, Ajax

G8T 7A1

RECRUITING

WISPer site in Trois-Rivières, Quebec, Trois-Rivières